Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
TERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.07 - $11.40
Previous CloseN/A
Volume294.76K
Average Volume (3M)1.01M
Market Cap
$272.37M
Enterprise Value$148.66M
Total Cash (Recent Filing)$12.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 19, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding87,297,630
10 Day Avg. Volume995,949
30 Day Avg. Volume1,005,106
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-168.74
Enterprise Value/Ebitda-1.50
Forecast
1Y Price Target
$18.00Price Target Upside476.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Terns Pharmaceuticals News
PremiumCompany Announcements
Terns Pharmaceuticals Reports 2024 Progress and Outlook
PremiumCompany Announcements
Terns Pharmaceuticals Appoints Andrew Gengos as CFO---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company reported positive early interim data from their Ph1/2 CARDINAL trial of '701, showing meaningful molecular and hematologic responses in patients.
Financial ReservesTERN has a substantial cash reserve of $358M, providing operational expenses coverage into 2028.
LeadershipThe new CFO, Andrew Gengos, brings considerable biotech, financial, and consulting industry experience, which is expected to positively influence the company.
Bears Say
Clinical And Regulatory RisksKey risks include clinical and regulatory risks that are most material to the Market Perform rating.
Market CompetitivenessA differentiation thesis is not clear at the moment, given the increasing competitiveness of both the CML and obesity treatment landscape.
Net LossTERN reported a net loss of $22M for 4Q24.
---
Ownership Overview
16.35% Insiders
8.96% Mutual Funds
0.41% Other Institutional Investors
65.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $3.06 and its highest was $11.40 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Terns Pharmaceuticals’s market cap is $272.37M.
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is May 19, 2025 which is in 51 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Mar 20, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.306 by $0.066.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -0.3.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 87,297,630 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.306. Following the earnings report the stock price went up 6.688%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Currently, no hedge funds are holding shares in TERN
---
Terns Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (476.92% Upside)
$18.00 (476.92% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 381.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.35%
12-Months-Change
Fundamentals
Return on Equity
-29.56%
Trailing 12-Months
Asset Growth
35.53%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
---
TERN Stock 12 Month Forecast
Average Price Target
$18.00
▲(476.92% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Ensysce Biosciences
―
Genfit SA
―
Akero Therapeutics
―
Best Analysts Covering TERN
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-30.13%
reiterated a buy rating last month
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -30.13% per trade.
---